Name: Latest research reports of Divi's Laboratories Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Divi's Laboratories Ltd.
Rating: 5
Author: ICICI Securities Limited

Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Star

6483.0000 -55.00 (-0.84%)

NSE May 23, 2025 15:31 PM

New 52W High in past week

Volume: 224.1K

Divi's Laboratories Ltd.

01 Jun 2016

6483.00

-0.84%

Divi's Laboratories

Buy: Divi's Laboratories Ltd.

Target

ICICI Securities Limited

ICICI Securities Ltd | Retail Equity Research Revenues grew 34.1% YoY to | 1095 crore (I-direct estimate: | 963 crore). The generics business grew 47% to | 566 crore (I-direct...

Number of FII/FPI investors increased from 826 to 922 in Mar 2025 qtr.